Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha 4 integrin antagonists.

David Y Jackson1

  • 1Department of Bioorganic Chemistry, Genentech Inc., 1 DNAWay, MS18, Francisco, CA 94080, USA. davej@gene.com

Current Pharmaceutical Design
|June 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity.

Nature cancer·2022
Same author

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Molecular pharmaceutics·2015
Same author

Involvement of alpha4 integrins in maintenance of cardiac sympathetic axons.

Autonomic neuroscience : basic & clinical·2005
Same author

Integrin alpha4beta1 function is required for cell survival in developing retina.

Developmental biology·2004
Same author

Alpha 4 integrins and vascular cell adhesion molecule-1 play a role in sympathetic innervation of the heart.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2002
Same author

Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.

Bioorganic & medicinal chemistry letters·2002
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
Same journal

Corrigendum to: miRNA in Diagnosis and Therapeutics of Tuberculosis: Importance in Latent and Brain Associated Pathologies.

Current pharmaceutical design·2026
See all related articles

Targeting alpha4 integrins, key mediators of leukocyte adhesion in autoimmune diseases, offers a promising therapeutic strategy. Inhibitors of these molecules show potential for treating inflammatory conditions like rheumatoid arthritis and multiple sclerosis.

Area of Science:

  • Immunology
  • Cell Biology
  • Pharmacology

Background:

  • Leukocyte accumulation in organs drives autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.
  • Alpha4 integrins (alpha4beta1, alpha4beta7) on leukocytes mediate adhesion to VCAM and MAdCAM on vessel walls, facilitating tissue entry and inflammation.
  • Elevated cell adhesion molecule (CAM) expression is linked to autoimmune pathology.

Purpose of the Study:

  • To discuss the rationale for targeting alpha4 integrins in autoimmune disorders.
  • To review existing alpha4 integrin antagonists and their development progress.
  • To explore methods for identifying lead molecules for alpha4 integrin antagonists.

Main Methods:

  • Review of scientific literature on alpha4 integrins, their ligands, and antagonists.

Related Experiment Videos

  • Analysis of preclinical data from animal models using alpha4 integrin inhibitors.
  • Discussion of drug discovery and development processes for alpha4 integrin antagonists.

    • Main Results:

    • Alpha4 integrins are validated drug targets due to their critical role in leukocyte adhesion and autoimmune pathogenesis.
    • Monoclonal antibodies targeting alpha4 integrins or their ligands demonstrate efficacy in animal models of inflammation.
    • Numerous alpha4 integrin antagonists have been identified and are progressing in drug development.

    Conclusions:

    • Targeting alpha4 integrins represents a significant therapeutic strategy for managing autoimmune and inflammatory diseases.
    • Inhibitors of alpha4 integrin-mediated adhesion hold promise for treating conditions such as asthma, rheumatoid arthritis, and multiple sclerosis.
    • Further research and development of alpha4 integrin antagonists are crucial for advancing treatment options.